Possible role of low-dose etoposide therapy for hemophagocytic lymphohistiocytosis by COVID-19

Int J Hematol. 2020 Jul;112(1):122-124. doi: 10.1007/s12185-020-02888-9. Epub 2020 May 12.

Author

Akiyoshi Takami¹

Affiliation

¹ Division of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine, 1-1 Yazakokarimata, Nagakute, 480-1195, Japan. takami-knz@umin.ac.jp.

No abstract available

Publication types

Letter

MeSH terms

Betacoronavirus / drug effects
Betacoronavirus / immunology
COVID-19
Coronavirus Infections / complications
Coronavirus Infections / drug therapy*
Coronavirus Infections / immunology
Cytokines / immunology
Dose-Response Relationship, Drug
Etoposide / administration & dosage
Etoposide / therapeutic use*
Humans
Lymphohistiocytosis, Hemophagocytic / complications
Lymphohistiocytosis, Hemophagocytic / drug therapy*
Lymphohistiocytosis, Hemophagocytic / immunology
Macrophages / drug effects
Macrophages / immunology
Pandemics
Pneumonia, Viral / complications
Pneumonia, Viral / drug therapy*
Pneumonia, Viral / immunology
SARS-CoV-2
Topoisomerase II Inhibitors / administration & dosage
Topoisomerase II Inhibitors / therapeutic use*

Substances

Cytokines
Topoisomerase II Inhibitors
Etoposide